Compare EPD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPD | MRNA |
|---|---|---|
| Founded | 1968 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.4B | 91.2B |
| IPO Year | 1998 | 2018 |
| Metric | EPD | MRNA |
|---|---|---|
| Price | $37.39 | $207.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 23 |
| Target Price | $41.67 | ★ $165.32 |
| AVG Volume (30 Days) | 3.7M | ★ 12.5M |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | ★ 5.98% | N/A |
| EPS Growth | ★ 106.96 | 21.77 |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $52,596,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $26.20 | $24.20 |
| Revenue Next Year | $4.90 | $11.31 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $31.35 | $22.28 |
| 52 Week High | $40.17 | $280.80 |
| Indicator | EPD | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 44.64 |
| Support Level | $36.96 | $181.02 |
| Resistance Level | $38.84 | $254.48 |
| Average True Range (ATR) | 0.75 | 17.25 |
| MACD | 0.05 | -5.34 |
| Stochastic Oscillator | 34.48 | 1.40 |
Enterprise Products Partners is a master limited partnership that transports and processes natural gas, natural gas liquids, crude oil, refined products, and petrochemicals. It is one of the largest midstream companies, with operations servicing most producing regions in the continental US. Enterprise is particularly dominant in the NGL market and is one of the few MLPs that provide midstream services across the full hydrocarbon value chain.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.